ArticleNeurology and therapy2026
Triple Preventive Therapy with OnabotulinumtoxinA, Fremanezumab, and Atogepant in Treatment-Resistant Chronic Migraine: A 52-Week Pilot Case Series (TRIPLE Cohort).
Marina Romozzi et al.PubMed ↗Publisher ↗
No numbers read from the abstract.